The growing spread of COVID-19 has changed the ways we live and work, and at this time, there are more questions than answers. As we continue to find normalcy in our daily routines, we realize that continuity is vital from a business perspective. The life science industry plays a critical role in the delivery and innovation of medicine to combat and prevent disease, such as the novel coronavirus.

Join leaders from the life sciences industry as they identify a path towards finding the right balance during these challenging times and provide insight on the role of ethics and compliance officers in addressing critical topics, such as:

• Our responsibility to patients and patient care, including privacy considerations (HIPAA, GDPR), the human impact of supply chain disruptions, Antitrust, and price gouging considerations.
  
  
• Physician access and business impact on sales and marketing. Specifically, how does a company stay compliant with regulations and ensure adequate access to customers? Compliance professionals need to align with Commercial to ensure safe access to customers, identify alternatives to current sales targets, and address the impact on incentive compensation to minimize risk.
  
  
• The importance of maintaining a flexible control environment and due diligence. When dealing with a crisis, are there specific controls that can be flexible? If so, adequate documentation should be maintained to demonstrate modifications made during the crisis and plans to return to baseline.
  
  
• Additional considerations include GXP's during vaccine development, risk mitigation during fast-tracking vaccine production, and the impact on clinical trials.